BUZZ-Viking Therapeutics gains after initiating Phase 1 trial for new weight-loss drug

Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX

0.00

June 24 - ** Shares of drug developer Viking Therapeutics VKTX.O up 5.7% at $36.78

** VKTX initiates phase 1 study of a new drug VK3019 for treatment of metabolic disorders and obesity

** VK3019 targets amylin and calcitonin receptors, which can help reduce appetite, control glucose and support weight loss

** Co to initiate phase 3 trial to evaluate oral drug VK2735 for treatment of obesity and overweight later this year

** Including session's moves, stock up 4.49% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.